Many women are aware that life expectancy is increasing and understand that this is an opportunity to maintain their health, fertility, and vitality for a longer period.
They strive to delay and even halt, as much as possible, the appearance of signs of aging, in order to enjoy full and healthy lives for many more years.
Menopause is a natural process in every woman's life, a significant crossroads between the fertile years and the third age.
What is Menopause?
Menopause is defined as the decline in the production of estrogen and progesterone, female hormones secreted by the ovaries.
This decline causes a variety of physiological and psychological changes in women and is primarily characterized by the cessation of menstruation.
When Does Menopause Begin?
Menopause typically begins between the ages of 45 and 55, but it may start earlier or later.
The age of menopause onset is influenced by genetic factors, lifestyle, and environmental factors.
Effects of Menopause:
The effects of menopause are diverse and vary from woman to woman. Common symptoms include:
- Hot flashes: Sudden heat attacks accompanied by sweating, chills, and dizziness.
- Sleep disturbances: Difficulty falling asleep, frequent nighttime awakenings, and poor sleep quality.
- Mood changes: Low mood, irritability, nervousness, and depression.
- Vaginal dryness: Can cause discomfort and irritation during intercourse.
- Menstrual cycle changes: Irregularity, increased or decreased bleeding, and complete cessation of menstruation.
- Weight changes: Tendency to gain weight, especially in the abdominal area.
- Osteoporosis: Decreased bone density, increasing the risk of fractures.
Duration of Menopause:
Menopause usually lasts several years, 7-10 on average.
After menstruation stops, women enter the third age.
In the animal kingdom, menopause is quite rare.
In fact, only five species are known to undergo this process, where the ovaries stop functioning.
Four of them—killer whales, short-finned pilot whales, beluga whales, and narwhals—live underwater.
The fifth species, of course, is humans.
The Melatonin Miracle: Promises of Youth and Fertility?
Is Melatonin the Key to Delaying Aging and Reversing Menopause?
Many women around the world look to Italy, where Dr. Walter Pierpaoli, a renowned physician, offers a unique treatment based on melatonin, the hormone known as the "sleep hormone." Dr. Pierpaoli calls this treatment the "Melatonin Miracle" and claims it can delay aging and reverse menopause.
A Breakthrough Study?
As early as 2001, Dr. Pierpaoli published a study presenting impressive results:
Women who took melatonin for an extended period reported significant improvement in their overall health, a delay in menopausal symptoms, and even cases of a return to fertility.
One of the most fascinating cases was of a woman who managed to conceive naturally three years after her periods had stopped.
Scientific Explanation?
Dr. Pierpaoli explains melatonin's effectiveness by its protection of the pituitary gland, which is responsible for producing many hormones, including those related to fertility and aging.
He claims that taking melatonin helps maintain the normal function of this gland, thereby delaying the biological processes that lead to aging and menopause.
A Blanket Recommendation?
Dr. Pierpaoli firmly believes that every woman should start taking melatonin as soon as possible, even if she does not wish to extend her fertility.
He believes melatonin provides many health benefits, ranging from preventing breast cancer to maintaining normal brain balance.
Unique Treatment:
However, it is important to note that the type of melatonin Dr. Pierpaoli uses is not available anywhere in the world except in Italy.
Women interested in this treatment method must come to his clinic in Italy and undergo a unique treatment process.
.
Treatment Based on Platelet-Rich Plasma (PRP)
A team of researchers led by Dr. Angelos Spakianoudis has developed an innovative treatment that may reverse the fertility clock for women who have experienced early menopause.
The treatment is based on Platelet-Rich Plasma (PRP), a substance derived from the woman's own blood and known for its ability to promote tissue healing.
Mechanism of Action:
The researchers believe PRP works by stimulating the regeneration of stem cells in the ovaries.
These stem cells, present in small numbers even after menopause, can produce new eggs.
PRP may encourage these cells to regenerate tissue and produce ovulation hormones, thereby restoring the menstrual cycle and fertility.
Encouraging Results:
In a first clinical trial, the team injected PRP into the ovaries of 30 women aged 46 to 49, all of whom wanted to have children.
As a result of the treatment, menstruation returned in about 67% of the women, and the team was able to isolate and fertilize eggs from most of them.
Further Development:
The team has not yet implanted any embryos in postmenopausal women but plans to do so in the coming months.
Simultaneously, they are studying the effects of PRP on the health of women not trying to conceive, examining the treatment's potential to delay menopausal symptoms and improve the health of many body systems.
New Study Shows Successful Results in Ovarian Rejuvenation!
The study, conducted by an experienced team of researchers, included 469 women, the largest group of women examined to date in the field of anti-aging and fertility treatments.
The study focused on examining the effectiveness of PRP treatment, based on injecting platelet-rich plasma into the ovaries, in stimulating tissue regeneration and function.
Encouraging Results:
The study is a retrospective observational study and included women of reproductive age with at least one ovary,
women with a history of infertility, hormonal changes, amenorrhea, and premature ovarian failure.
During the patient's first consultation, a detailed reproductive history was recorded, a pelvic scan for ovarian size was performed,
and a hormonal analysis was conducted for Follicle-Stimulating Hormone (FSH), Anti-Müllerian Hormone (AMH), Estrogen (E2), and Luteinizing Hormone (LH).
In the study, 469 women with a history of infertility, hormonal changes, amenorrhea, and premature ovarian failure, whose hormone levels were recorded up to four months after treatment, were included.
The volume of peripheral blood required to prepare 6-8 ml of PRP for injection was 40-60 ml.
The initial platelet concentration in the peripheral blood sample was about 25,000/μL, while the prepared PRP had a concentration of 900,000/μL.
A volume of about 2-4 ml per ovary, depending on ovarian volume, was injected into the ovary.
The PRP intervention had significant effects on FSH concentration at the α = 0.05 level.
Statistically significant increases in normal FSH and E2 values were seen at three and four months after the PRP intervention for all age groups.
The conclusions from the study are that the results show that intraovarian PRP injection affects the improvement of ovarian tissue and function.
Future controlled clinical studies are needed to elucidate the use of PRP in ovarian rejuvenation before offering it routinely through clinical treatment.
Additional Study
Focused on studying the changes that occur in human ovaries with age.
The researcher accumulated extensive knowledge on the subject, and her study presents groundbreaking discoveries that could significantly impact our understanding of the female aging process and the development of new treatments.
Challenge of Obtaining Tissues:
One of the biggest challenges in studying ovarian aging is obtaining suitable tissues for research.
The researcher managed to overcome this challenge through collaboration with 15 volunteers who donated their ovaries after surgery.
These ovaries were divided into three age groups: young (18-28 years), middle-aged (36-39 years), and older (47-49 years).
Innovative Techniques for Studying Gene Expression:
The authors used advanced techniques that allow measuring gene expression at the single-cell level.
These techniques allowed them to analyze the changes in gene expression in eight different types of ovarian cells over age.
Fascinating Findings:
In-depth analysis of gene expression revealed a complex picture of changes occurring in the ovaries with age.
It was found that:
- Significant differences in gene expression: There are significant differences in gene expression between ovaries of women of reproductive age and ovaries of menopausal women. These differences reflect changes in the functions and characteristics of ovarian cells over age.
- Cellular senescence as a central factor: Cellular senescence was found to be a central factor in ovarian aging. Senescent cells in the ovary are characterized by poor function, impaired regenerative capacity, and accumulation of molecular damage.
- Link between cellular senescence and inflammation: A link was found between cellular senescence and inflammation in the ovaries. Senescent cells secrete inflammatory molecules, which cause further damage to healthy cells and contribute to the progression of the aging process.
- FOXP1: A key transcription factor: A key transcription factor regulating aging processes in the ovary was identified - FOXP1. FOXP1 levels decrease with age, which promotes the aging process.
- Quercetin: A new hope for treatment: Quercetin, a natural compound with anti-aging properties, has been shown to inhibit ovarian cell senescence and help improve ovarian reserves in mice.
Detailed Experiment on the Effect of FOXP1:
The researchers conducted another experiment examining the effect of FOXP1 on ovarian aging.
They reduced FOXP1 levels in mouse granulosa cells and observed the effect on the aging process. It was found that:
- Accelerated ovarian aging: Reducing FOXP1 led to accelerated ovarian aging in mice.
- Changes in gene expression patterns: Significant changes in gene expression patterns were observed in granulosa cells with reduced FOXP1 levels.
These changes are associated with known aging processes. - Increase in senescence markers: Increases were observed in levels of markers associated with cellular senescence, such as SA-β-gal activity and lipofuscin accumulation.
- Increased cell death: More granulosa cells died by apoptosis (programmed cell death) in mice with reduced FOXP1 levels.
Conclusions:
The study's findings contribute greatly to our understanding of the mechanisms of human ovarian aging. It was found that:
- Cellular senescence is a central factor in ovarian aging.
- A transcription factor called FOXP1 plays a central role in regulating aging processes in the ovary.
- Reducing FOXP1 levels leads to accelerated ovarian aging.
- Quercetin, a natural compound with anti-aging properties, may represent a potential treatment for ovarian aging.
References:
https://pubmed.ncbi.nlm.nih.gov/11226744/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355907/
https://www.worldscientific.com/doi/10.1142/S2661318223500032
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243509/
https://www.ivf-embryo.gr/en/prp-ovarian-rejuvenation
https://www.bloomberg.com/features/2023-menopause-age-drugs-women-longevity/
https://www.nature.com/articles/s43587-024-00607-1
https://academic.oup.com/humupd/article/18/1/73/853086?login=false
https://www.nature.com/articles/nrm3823
https://pubmed.ncbi.nlm.nih.gov/32005271/
https://www.sciencedirect.com/science/article/abs/pii/S001429992400027X
💬 תגובות (0)
היו הראשונים להגיב על המאמר.